|
|
|
| Comparison of Efficacy and Safety of Dabigatran Ester,Rivaroxaban,and Warfarin in the Treatment of Atrial Fibrillation |
| LEI Xueting, WANG Ni |
| Department of Cardiology,People's Hospital of Shanyang County,Shangluo Shaanxi 726400 |
|
|
|
|
Abstract 【Objective】To compare the efficacy and safety of dabigatran ester,rivaroxaban,and warfarin in the treatment of atrial fibrillation.【Methods】A retrospective study was conducted on 243 patients with atrial fibrillation admitted to our hospital from January 2020 to January 2022. Patients were divided into group A,group B,and group C by random number table method,with 81 patients in each group. All patients in the three groups received routine treatment for atrial fibrillation. On this basis,Group A patients were given dabigatran ester capsules,Group B patients were given rivaroxaban tablets,and Group C patients were given warfarin sodium tablets. The clinical efficacy and coagulation related indicators including thrombin time (TT),activated partial thromboplastin time (APTT),prothrombin time (PT),and fibrinogen (FIB) before and after treatment were compared among three groups. The incidence of adverse reactions during treatment among the three groups was compared as well.【Results】After 6 months of treatment,there were no statistically significant differences in the total effective rates among Group A,Group B,and Group C (P>0.05). After treatment,the TT,APTT,and PT of the three groups of patients were all higher than those before treatment (P<0.05). And there was no statistically significant difference in FIB among the three groups (P>0.05). There was no statistically significant difference in TT,APTT,PT,and FIB between Group A and Group B after treatment (P>0.05). However,after treatment,TT,APTT,and PT in Group A and Group B were significantly higher than those in Group C (P<0.05). The total incidence of adverse reactions in Group A and Group B was lower than that in Group C (P<0.05); And there was no statistically significant difference of adverse reactions between Group A and Group B (P>0.05).【Conclusion】There is no significant difference in the efficacy of dabigatran ester,rivaroxaban,and warfarin in anticoagulant therapy for patients with atrial fibrillation. However,compared to warfarin,dabigatran ester and rivaroxaban are safer and have a more significant improvement in coagulation indicators.
|
|
Received: 10 May 2022
|
|
|
|
|
|
[1] ANDREAS R,CHRISTINA M,ANN-KATHRIN O,et al. Early rhythm control therapy in patients with atrial fibrillation and heart failure[J].Circulation,2021,144(11):845-858.
[2] 于明石.不同强度华法林抗凝治疗非瓣膜病性房颤患者的长期疗效观察[J].中国冶金工业医学杂志,2022,39(2):144-145.
[3] 吴建维,侯晓霞,杨毅,等.欧洲心脏病协会心房颤动管理指南[J].中国卒中杂志,2011,6(11):898-910.
[4] 张烨屏.30例心房颤动合并急性冠状动脉综合征患者抗栓治疗效果分析[J].中西医结合心血管病电子杂志,2019,7(16):171.
[5] 陈太波,荆志成,方全,等.关注高龄心房颤动患者的抗凝治疗[J].中华心血管病杂志,2022,50(1):20-24.
[6] 谭素敏,杨磊,边原,等.心房颤动患者左心耳封堵术后抗栓策略[J].中国新药与临床杂志,2022,41(1):12-16.
[7] COLEMAN C I,THOMPSON S,ASHTON V,et al. Rivaroxaban versus warfarin in African American patients with nonvalvular atrial fibrillation[J].J Natl Med Assoc,2020,112(4):395-401.
[8] PANIBRATIUK O A,YAKOVLEVA O А. Warfarin therapy in patients with coronary heart disease and atrial fibrillation: drug interactions and genetic sensitivity to warfarin[J].Ukrain Bioch J,2020,92(3):77-85.
[9] 李佳乐,赵莉.达比加群酯抗凝治疗合理性和安全性评价[J].中国医院药学杂志,2019,39(21):2176-2180.
[10] ARACHCHILLAGE D J,SHARON A,JESSICA G,et al. Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding[J].Br J Haematol,2019,184(5):808-816.
[11] 左旭锐,张晓雨,吕春晓,等.丹参影响华法林抗凝作用的研究进展[J].中药新药与临床药理,2021,32(9):1412-1415.
[12] 杨蕾,杜秋红.达比加群酯在冠心病PCI合并心房颤动高出血风险患者抗栓治疗中的作用[J].中国动脉硬化杂志,2020,28(1):54-58.
[13] 成俊,谭均,赵耘,等.凝血酶浓度对纤维蛋白胶预防术后脑脊液漏的影响[J].中国组织工程研究,2021,25(4):570-575. |
|
|
|
2023, Vol. 40 
